A promising result can answer one question and immediately raise another.
Will it hold up beyond the setting where it was first developed?
That's one reason multicenter clinical validation matters.
In a peer-reviewed study published in Diagnostics, researchers evaluated the PanGIA Analysis System in 283 participants recruited across 26 U.S. urology practices.
Using first-morning urine samples and machine-learning analysis of biomolecular patterns, the study reported 97.8% sensitivity and 97.3% specificity for prostate cancer detection in the study population.
Those numbers matter.
So does the context behind them.
Evaluating a diagnostic approach across multiple clinical sites adds another layer of evidence for how the technology performs beyond its initial development.
For PanGIA Biotech, this study represents more than a promising result from a single setting.
It adds multicenter clinical evidence to the growing body of research supporting the platform's potential for prostate cancer detection.
#ProstateCancer #ClinicalValidation #LiquidBiopsy #Diagnostics #MachineLearning
14
A promising research finding can get people's attention.
But when the information could eventually influence decisions about someone's health, promising isn't enough.
Researchers have to keep asking harder questions.
Can the findings be repeated?
Do they hold up when the technology is evaluated with more people, in different settings, and under different conditions?
That process is part of how promising science begins building a body of evidence.
PanGIA Biotech's research has followed that progression.
Its prostate cancer research moved from earlier development and validation work presented at ASCO to a multicenter clinical validation study involving 283 participants across 26 U.S. urology practices.
Researchers have also continued evaluating the underlying PanGIA Analysis System across additional cancers, biofluids, and disease applications.
Each new application brings its own questions and requires its own research and validation.
Because good science isn't about proving what you hope is true.
It's about continuing to test whether the evidence says it is.
#CancerResearch #ClinicalValidation #Diagnostics #LiquidBiopsy #PrecisionMedicine
9
Different cancers present different biological challenges.
But does identifying them necessarily require an entirely different diagnostic platform for each?
PanGIA Biotech's published research has evaluated its Analysis System as a machine-learning platform for the non-invasive diagnosis of multiple cancers.
Using urinary biomolecular patterns, researchers reported the platform's ability to differentiate cancer from non-cancer across the cancer types evaluated.
Each cancer application still requires its own research and validation.
But the findings point toward an intriguing possibility:
What if expanding cancer detection doesn't always require developing an entirely new diagnostic platform?
#CancerDetection #LiquidBiopsy #Diagnostics #MachineLearning #PrecisionMedicine
5
Screening usually begins because we know what we're looking for...a certain cancer, known risk, or recommended screening interval.
But what if disease-associated biological information could provide clues beyond what we're already looking for?
That's part of the opportunity behind earlier cancer detection.
PanGIA Biotech's research uses biomolecular pattern recognition to analyze disease-associated information found in urine, combining proprietary hydrogel-based microarray technology with machine learning.
Earlier detection isn't simply about looking sooner.
It's about learning what to look for before the disease makes itself known.
#EarlyDetection #CancerDetection #Diagnostics #ClinicalResearch #PrecisionMedicine
5
A urine sample may look remarkably ordinary.
PanGIA Biotech has found complex biological patterns within it that might otherwise be missed.
The PanGIA Analysis System uses first-morning urine and proprietary hydrogel-based microarray technology to capture and analyze complex biomolecular patterns associated with disease.
Machine learning helps identify meaningful patterns within that biological information.
It’s a sophisticated approach that begins with a remarkably familiar sample.
#CancerDetection #LiquidBiopsy #Diagnostics #MachineLearning #PrecisionMedicine
9
Genomic sequencing has opened remarkable new possibilities in cancer care.
But it isn't the only way researchers are learning to read the biological information associated with disease.
PanGIA Biotech is pursuing a different approach.
Using a non-invasive urine sample, proprietary hydrogel-based microarray technology and machine learning, PanGIA analyzes biomolecular patterns without relying on sequencing.
That distinction matters beyond the technology itself.
PanGIA's sequencing-free approach is designed to support scalable implementation and broader access without relying on next-generation sequencing or PCR amplification.
The future of cancer detection may not depend on choosing between sophisticated science and greater accessibility.
The opportunity is finding ways to advance both.
#CancerDetection #LiquidBiopsy #Diagnostics #MachineLearning #PrecisionMedicine
10
Imagine two patients with the same concern.
One lives near a major medical center with access to advanced diagnostic capabilities.
The other lives hours away.
Their need and biology may be similar.
But their options may not be.
As cancer detection advances, that gap matters.
The challenge isn't simply developing increasingly sophisticated diagnostics.
It's finding ways to make advanced testing practical for more healthcare settings and the patients they serve.
The future of early detection shouldn't depend on whether the right technology happens to be nearby.
#GlobalHealth #CancerDetection #Diagnostics #HealthcareAccess #PrecisionMedicine
4
Imagine taking a hard hit during a sports game.
You get up, remove your helmet, and walk off the field.
There may be no broken bones, bleeding, or other obvious injury for someone looking at you from the sidelines.
But what can we learn about what's happening beneath the surface?
That's one of the challenges researchers face when studying traumatic brain injury.
This past November, PanGIA Biotech presented findings from a proof-of-concept study evaluating cerebrospinal fluid biomolecular patterns associated with traumatic brain injury using the PanGIA Analysis System (PAS) at the ISLB Annual Congress.
The analysis showed distinct separation between samples containing TBI-associated levels of analytes and those containing normal levels.
The findings support further investigation of PAS for identifying traumatic brain injury through cerebrospinal fluid. Further clinical studies are needed to validate the findings.
Sometimes understanding what happened requires looking beyond what we can see to what the biology may be telling us.
#Neurology #ClinicalResearch #TraumaticBrainInjury #Diagnostics #MachineLearning
10
Imagine knowing someone you love isn't well, but no one can tell you why.
You trust the physicians, follow through with the recommended testing, and make appointments with specialists who may be able to help.
Still, the answer remains elusive.
For some families affected by rare diseases, that search can continue for years.
What if patterns within the biology could help researchers learn something that individual signals alone might not reveal?
At this past November's ISLB Annual Congress, PanGIA Biotech presented research exploring whether machine learning and biomolecular pattern recognition could help identify disease-specific signatures across multiple rare diseases.
The research also explored automated signature tracking as part of PanGIA's approach to recognizing complex biological patterns.
Research can't give families back the years they've already spent searching for answers.
But learning to recognize meaningful biomolecular patterns may help researchers better understand what the biology is revealing.
#RareDisease #ClinicalResearch #MachineLearning #Diagnostics #PrecisionMedicine
2
You're sitting across from a physician waiting for answers.
You've explained what you've been experiencing, completed the testing and shared your medical history.
Now your physician has to make sense of all that information and determine what it may be telling them.
As technology becomes more sophisticated, artificial intelligence can help analyze complex information and recognize patterns that may be difficult to identify otherwise.
But technology doesn't replace the expertise, judgment and human understanding a physician brings to the conversation.
It can give them another tool to help make sense of complex biological information.
PanGIA Biotech uses machine learning as part of its approach to biomolecular pattern recognition, analyzing complex biological information for patterns associated with disease.
It's another source of information that may help physicians help you.
Because the value of AI in medicine isn't simply what the technology can recognize.
It's how that information can support the humans making decisions about human lives.
#ArtificialIntelligence #MachineLearning #Diagnostics #PrecisionMedicine #ClinicalResearch
3
A patient walks into the exam room with a list of symptoms.
The lab results arrive.
The imaging is reviewed.
The medical history is discussed.
An experienced physician rarely bases a diagnosis on a single observation.
They look for the pattern that tells the bigger story.
What if biomolecular patterns could reveal information that individual signals alone might miss?
That question sits at the heart of PanGIA Biotech's approach to biomolecular pattern recognition.
Rather than relying on a single biomarker, PanGIA's technology evaluates complex biomolecular patterns using proprietary hydrogel-based microarray technology and machine learning.
Sometimes the biggest breakthrough isn't finding another clue.
It's recognizing the pattern the clues have been creating all along.
#MachineLearning #Diagnostics #PrecisionMedicine #ClinicalResearch #Biotechnology
🤖 Made with AI
4
It was supposed to be a routine dental cleaning.
Thirty minutes for a quick polish, then back to work.
But then the dentist noticed something that didn't belong.
What if oral cancer leaves detectable clues before anything suspicious can be seen?
At the 2026 AACR Annual Meeting, PanGIA Biotech's research team reported that the PanGIA Analysis System (PAS) distinguished oral cancer-associated biomolecular analytes from oral samples using AI-enabled pattern recognition.
These findings add to PanGIA Biotech's growing body of published evidence evaluating non-invasive approaches to identifying disease-related biomolecular signatures.
Sometimes the earliest clues aren't waiting to be found. They're waiting to be recognized.
#OralCancer #ClinicalResearch #Diagnostics #CancerResearch #PrecisionMedicine
10
Some cancers don't announce themselves.
They quietly grow and spread before symptoms ever appear.
Many times the patient feels fine, so life goes on because nothing seems out of the ordinary.
There are no symptoms to investigate or reason to schedule another appointment.
Until… an unexpected finding changes the conversation.
Could cancer be leaving detectable clues long before patients know something is wrong?
At the 2026 AACR Annual Meeting, PanGIA Biotech's research team reported that the PanGIA Analysis System (PAS) distinguished urinary biomolecular patterns across multiple cancer models, including breast, brain, bone, and hematologic cancers.
Those findings add to PanGIA Biotech's growing body of published evidence evaluating biomolecular pattern recognition as a non-invasive approach to cancer detection.
The future of early detection may depend less on waiting for symptoms and more on recognizing the signals that come first.
#CancerResearch #EarlyDetection #LiquidBiopsy #ClinicalResearch #PrecisionMedicine
4
It started with prostate cancer.
But one question naturally led to another.
If disease leaves behind recognizable biomolecular patterns, why would those patterns exist in only one condition?
That question has helped shape PanGIA Biotech's published research.
Over time, the company's scientific work has expanded beyond prostate cancer to include multi-cancer detection, Parkinson's disease, traumatic brain injury, rare diseases, and additional areas of investigation using AI-enabled pattern recognition and non-invasive biofluids.
Each study explores a different clinical challenge.
Together, they point toward something much bigger.
Not a separate technology for every disease.
A platform designed to recognize the unique biological patterns different diseases leave behind.
Sometimes the most important scientific breakthrough isn't answering one question.
It's discovering a better question to ask.
#ClinicalResearch #MachineLearning #PrecisionMedicine #CancerDetection #Biotechnology
15
Most of us associate Parkinson's disease with tremors and shaking hands.
But the disease often begins long before anyone can see it.
Because the brain is remarkably resilient, it can quietly compensate for years before visible symptoms begin to appear.
By the time the first visible symptoms appear, an estimated 30% to 50% of key dopamine-producing cells may already be gone. (Cheng et al., 2010)
That reality has researchers asking different questions, like:
What if meaningful biological changes could be
recognized long before the first obvious symptom?
PanGIA Biotech's published research is part of that growing conversation.
Using AI and machine learning, PanGIA Biotech researchers identified urinary biomolecular patterns associated with Parkinson's disease, expanding the company's published scientific work beyond oncology into other complex diseases.
Because the future of early detection isn't waiting for symptoms.
It's learning to recognize the signals that come first.
#ParkinsonsDisease #EarlyDetection #MachineLearning #ClinicalResearch #PrecisionMedicine
7
It was an ordinary Tuesday until she got the call that brought her to her knees.
In that single moment, her world changed.
Like so many families facing a cancer diagnosis, one thought lingered:
If only we’d known sooner.
Unfortunately, stories like this one remain far too common because many cancers are not detected until they have reached a later stage.
In today’s age of medical and technological advancement, that reality is hard to reconcile.
Yet, a new global study estimates that nearly one-third of people who develop one of 17 major cancers may never receive a diagnosis.
The study also projects that by 2050, nearly half of diagnosed cancers worldwide will still be identified only after the disease has spread.
Those findings reinforce why early cancer detection remains one of the greatest opportunities in modern medicine.
That is one reason PanGIA Biotech continues looking for ways to save lives, change lives, and give back.
That mission is reflected in years of peer-reviewed research and scientific presentations focused on its proprietary AI-enabled, machine learning-driven platform.
The platform is being developed for non-invasive cancer detection using urine and saliva across multiple cancers and other diseases.
Changing an oncology patient’s story often begins long before treatment.
It begins with finding cancer sooner.
#CancerDetection #EarlyDetection #PrecisionMedicine #ClinicalResearch #Oncology
Some of the most important breakthroughs don't happen because scientists discover something new.
They happen because someone decides to look at a familiar problem differently.
It's no secret that cancer is extraordinarily complex. In fact, there are more than 200 distinct types of cancer, each with its own unique biological characteristics and treatment considerations.
Every tumor leaves behind biological signals, but those signals rarely exist in isolation.
That reality led the researchers behind PanGIA Biotech's foundational NuTec technology to ask a different question:
What if meaningful insights aren't found in a single biomarker, but in the relationships between many biomolecular signals?
That question changed how our researchers approached the problem.
Rather than focusing on identifying a single biomarker, they explored whether complex biomolecular patterns could reveal insights that individual markers might never show on their own.
That shift in thinking became the scientific foundation for the pattern-recognition approach behind the PanGIA Analysis System (PAS), which continues to guide the company's published research and clinical development.
Because sometimes the biggest breakthrough isn't discovering another clue.
It's learning to see the whole picture.
#CancerDetection #PrecisionMedicine #MachineLearning #ClinicalResearch #Oncology
10
When most people hear the term "liquid biopsy," they immediately think of a blood sample.
That's understandable.
Blood-based testing has received enormous attention over the past decade.
But PanGIA Biotech researchers are exploring a broader question:
What if valuable biological information exists in other biofluids as well?
Urine, oral samples, cerebrospinal fluid, and other biofluids may each provide a different window into human health and disease.
Understanding what those biofluids can reveal may create new opportunities to detect, monitor, and better understand a wide range of conditions.
That's one reason PanGIA researchers presented research at the International Society of Liquid Biopsy Annual Congress exploring the scalability of biomolecular profiling across diverse non-blood biofluids.
The future of diagnostics may not come from studying one biofluid better.
It may come from understanding what each biofluid can uniquely reveal.
#LiquidBiopsy #CancerDetection #ClinicalResearch #MachineLearning #PrecisionMedicine
7
As soon as the doctor walked into the room, he asked the same question.
"Has it come back?"
His doctor understood why.
Bladder cancer has one of the highest recurrence rates among common cancers, making ongoing monitoring an important part of life for many patients.
That's one reason PanGIA Biotech continues advancing non-invasive approaches to cancer detection and disease monitoring.
At the 2026 American Association for Cancer Research (AACR) Annual Meeting, PanGIA Biotech presented research showing its machine learning platform could distinguish multiple cancer signatures from a simple urine sample, including bladder cancer.
The research highlighted the potential for:
• A simple, non-invasive urine sample rather than an invasive procedure
• Machine learning capable of recognizing distinct biomolecular patterns
• A platform designed to expand beyond a single cancer type through pattern recognition
Because no one should have to live between appointments wondering if anything has changed.
#BladderCancer #CancerDetection #PrecisionMedicine #ClinicalResearch #Oncology
8
He went in because of back pain.
But the scan revealed something neither he nor his physician expected.
A mass in his kidney.
Stories like this are surprisingly common.
Many kidney cancers are discovered incidentally while physicians are investigating something completely unrelated.
According to the Mayo Clinic, an estimated 50% of all kidney cancers are discovered entirely by accident.
Why? Because kidney cancer can develop quietly, often without obvious symptoms during its earliest stages.
That reality continues driving interest in new approaches to cancer detection that may help identify meaningful biological changes before symptoms become apparent.
PanGIA Biotech researchers have presented data demonstrating the ability of the PanGIA Analysis System (PAS) to distinguish multiple cancer-associated biomolecular patterns through urine-based analysis, including renal cancer models.
Because finding cancer by accident may not be the future patients deserve.
#KidneyCancer #CancerDetection #Oncology #LiquidBiopsy #ClinicalResearch
8




















